Samsung Epis Holdings Expands Into New Drug Development
The bio-investment holding company now manages 13 non-listed subsidiaries.
Samsung Epis Holdings, a bio-investment holding company, operates as a parent entity focused on the control of its subsidiaries,. The company was established on November 3, 2025, following a corporate split on November 1,. It subsequently listed on the stock market on November 24, 2025.
Consolidated revenue is generated entirely by Samsung Bioepis, which focuses on the development and commercialization of biosimilars. This subsidiary has completed the global commercialization of 11 biosimilar products for various conditions, including autoimmune and oncological diseases. The company utilizes two primary sales channels, which include partnerships with pharmaceutical firms or private label companies to reach wholesalers and hospitals.
Samsung Bioepis is currently expanding its business scope from biosimilars into new drug development,. The company is prioritizing antibody-drug conjugates, which are designed to precisely target disease-causing factors. Since 2023, the company has conducted research in this field and now operates a pipeline with two new drug candidates, specifically Nectin-4 ADC and EGFR-HER3 ADC,.
Other subsidiary activities include the development of next-generation bio technology platforms at EpisNexLab, which was founded on November 11, 2025,. Additionally, the company opened a research and development center in China on June 30, 2026. The group also entered into a convertible bond investment agreement with G2GBio on March 16, 2026.